AVBP Stock Forecast & Price Target

ArriVent BioPharma is viewed favorably because its lead EGFR-targeted asset firmonertinib has shown a highly competitive profile in 1L PACC, with 68% confirmed ORR, 16.0-month PFS, and 53% CNS ORR, supporting the potential of its ALPACCA program. Its ARR-217 data also look encouraging despite being early, with 45% headline ORR, 38% confirmed ORR at 6mg/kg, 26% cORR at active doses, and estimated mPFS tracking at 7.1 months, suggesting meaningful clinical validation in mCRC. The outlook is further supported by a broader precision-oncology pipeline, including ARR-002, plus multiple catalysts through 1H27, 2H27, and YE27 that could drive re-rating if efficacy and safety remain strong.

ArriVent BioPharma is facing a weakened investment case because its lead program firmonertinib missed the Phase 3 FURVENT trial’s PFS primary endpoint, with the control arm unexpectedly outperforming and the hazard ratio of 0.75 failing to reach statistical significance (p=0.0654). Although the BICR result showed 11.0 months of median PFS versus 9.5 months and secondary endpoints like confirmed objective response rate improved to 60% from 33%, the failure to clear the main efficacy bar raises concerns about the drug’s competitive profile in 1L EGFR ex20ins+ NSCLC. With a still clinical-stage platform and a pipeline that includes ARR-217, the company remains highly dependent on future data to offset the setback and sustain long-term value creation.